{"name":"Ayala Pharmaceuticals, Inc,","slug":"ayala-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AL101","genericName":"AL101","slug":"al101","indication":"Solid tumors with PI3K/AKT/mTOR pathway alterations","status":"phase_2"}]}],"pipeline":[{"name":"AL101","genericName":"AL101","slug":"al101","phase":"phase_2","mechanism":"AL101 is an inhibitor of the PI3K/AKT/mTOR pathway.","indications":["Solid tumors with PI3K/AKT/mTOR pathway alterations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-14","type":"pipeline","source":"BusinessWorld Online","summary":"AC Health opens first St. Joseph Drug store in Metro Manila - BusinessWorld Online","headline":"AC Health opens first St. Joseph Drug store in Metro Manila","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxa2RkbUpXbUZlOFk4NnhfYXpCTWhYcmJMa1Y5ZzYxdFZhYVRwcll0WDcyYXg0SXdiUl9UVVlaREd0NFV2TkFjMDk2aGExQzVIZ2c4?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ADXS Stock Price, News & Analysis | Ayala Pharm - Stock Titan","headline":"ADXS Stock Price, News & Analysis | Ayala Pharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOeUM0RVBXVWh1MnM2UEN6QjV6d0t6aDBXQ0xwLWlaZk9QQUVzMXZiME04V0JLUHgtb2hDOW9wWTB1UEhCQWI0NVgtUF8wSE1tdU5pc3pmOFNIR3h4aXY2YWZoMTRYQnp6cEFqM1NJTlVTYTNlR2N1Q24tbmlBR0xCOVMzNGxVVVRkck4xdVNtWUxqM3d6MDB0NWZwb083ajdlYWVpV3BFTk1mcGFrQWQ1eXZKV2I5c09ScklhRDNNQ2ludEExdlVMRlVucThrVUlnZUdHTkUxbngySUIyc3h3M3VPZm5tdnFLUlBlanBzRTJZTmdUWXNLdkhybHFKYVBFNTFCbTM5eWpYWVBWc3c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Business Wire","headline":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxPZzJPVHpBXzVnenRmUWZaVHRyT3NHTnQ4VzUwR1dERERJa1ZBekhWajY2X29LSTkzb0RtWWFzdmUzQ2VhR2NPam9uaXZxbEt5VWdjcEhyVmwzVXMtRFczblYtcDE0VzJwRHZ3RWJlM0NxY3BCb2V6UjF6RFpwYzU2b3RlZklLbFdDbnR1d0RuYmhHenJqWGZxaXRhTDlBSGJEdHBncXk2MjdxRjNfQ1NjWnhWQ3NRWk1Cc185bEQ0ai1ST2FnOW9UUG43eGxoNW5jWUw0aGloZkFidzJrUU01R29VanJfQ1JONGd0NjhCS0lMbFItVk1JQUJvaFlxOE1obUN1RTdELXNFVkl3V084ck9pY09xNURhdGNObmtnTjhKS3pmMVQ4YlVGZzkwaTIyY1hKS2pfQkQ0NDZaN0FJakdlUWhRVVBTNWJWNHN4V0QzZTFLZFpvRS1UNFlRMlg0YUE?oc=5","date":"2025-01-30","type":"trial","source":"BioSpace","summary":"OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pip","headline":"OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmace","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNaVRvZkN3Ym1LUG00UGxDTUNRZGpZSDBOTlBlenJJc3MxZEVoRWpCbGlYbVNGRldFNXd3alFMcG12cXF4U2NkSGxUMjg3bjF0QlY2eVJYQzhhc3pFRVoxZE82b1E0N2J3bkVCOEdZNGZBMldnZklldnVLaWQ1S2E4MnhoMUt1SUQ3aFpuekx3UVNZXy0zZTdackFuVGVmbUVERkl4aGw3dFJfVFBY?oc=5","date":"2025-01-29","type":"pipeline","source":"Fierce Biotech","summary":"OS Therapies pays $8M for full IP rights to its lead drug, gains 2 more cancer assets in the process - Fierce Biotech","headline":"OS Therapies pays $8M for full IP rights to its lead drug, gains 2 more cancer assets in the process","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOYVhtbEVrU1lJdjNvU0lHU2xkbVNnQmt5aWN5R1hWMTNSc2RNYUgxWFpCWmVJdUp3SDgxX3pIZ21JeVVjdW1KdzRDUnZmZ0I2OHlFRG1WRVlGYTJUTlFvQ19RZzVzRWVWV1RENTFkVEV0Z2t1V29EbDJqMWc4S2huajRvZk9nYzFl?oc=5","date":"2024-05-09","type":"pipeline","source":"Yahoo Finance","summary":"Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - Yahoo Finance","headline":"Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxONDZrQUQ2ZC1WN0tDWHFaZGlzQ1R1aVlyZlN5VFhaLUFuZ09Rd2dvMHQ5NkI4YTJQS2dwOTIzR3NrWm5JQklFMGNwTEFUNFdLVE1ZZFhyb2luc1daV1F3UVI4VHR6em1zSFBXMjhqWGs2NVh3TG5FMjAyZDNxQXA0cVBzLUh3VHVvRDVhaVcwQmd0SHJNRTlSNTkyci3SAVZBVV95cUxQRUlSZ2JFSkxSWEppZXpmM2lCdjBqclNtTmxtcHJKUGtob0c5NEFCbzBjY09VcW9fWXVsbWJFTEY5MWtoa1JMblJPTVRROWE3UGE1TDRJdw?oc=5","date":"2024-04-23","type":"deal","source":"Law360","summary":"Pre-Merger Deal Prompts Pharma Co. Derivative Suit In Del. - Law360","headline":"Pre-Merger Deal Prompts Pharma Co. Derivative Suit In Del. - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPeFQxUTR6YVZzOU9iVkE2MDhwM1d0U25LMXkwVmNlNG5QMEtQTDJCMXc3b2Mxdm5LaFZ3MVZObTBRT0hfaDIwZmY3VHplY1hiRm1yUEFCMFlPTW5Mak91T2tCdG9fQkhkYllYdTN1cm9keHFSZVN3ODZlQkJCSzFweTJGV09ma0ZDb3o0NjVpcmhYVU95Q3pn?oc=5","date":"2023-10-19","type":"deal","source":"Yahoo Finance","summary":"Ayala Pharmaceuticals Announces Closing of Merger with Biosight - Yahoo Finance","headline":"Ayala Pharmaceuticals Announces Closing of Merger with Biosight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOYk02VG1vbDR6VExCcDVjZkFUVTE2eDBfTzlwX1R5R29zekw0VTFYRGZXekN3NUhNYjNoSDJUMGM5XzQ5aWtWaC1SX21PV2Q3SjYzQnhPMFZyamlDSm53WG5ybmFYSTlMQlNzY0EzQmdWV3JlUU44aDZBakh5NkZkX0tVNklBNmlSN2V4TTdYR25jeE0zaDdCbWR5bmJScnBNSE0yVms5aXdHSTZwQWlZ?oc=5","date":"2023-07-27","type":"deal","source":"Contract Pharma","summary":"Ayala Pharmaceuticals, Biosight Enter Definitive Merger Agreement - Contract Pharma","headline":"Ayala Pharmaceuticals, Biosight Enter Definitive Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNRjR2cGN1TC1Jclc3c3B2dXhBS25pd0ZGdTB5QVhTNk5tbFZOeG9fWlZpMzdaZGdsci1fRHN4QmF5VXdHSHpkdHI4Q0tMemRmbnRUTW5laDlieXJ6TlhwN3F0bjJxUHUtU3d2dXRTdmdyZV9yQk5vMnh1cVRWS2twTQ?oc=5","date":"2023-01-20","type":"deal","source":"NJBIZ","summary":"Advaxis completes merger to become Ayala Pharmaceuticals - NJBIZ","headline":"Advaxis completes merger to become Ayala Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBLZERONmVqbk9qVGVfU0o4OE1weDN3bFpBcnIzSk9iRmZmMFdzYnBsMkRycTZxQnVfOEZQUWgyVWdOb3ZQWVhfSHJwTGdTaDNLdDdqbGRLb25WWTNtRUxENVlTYjA2RDc3T0t6bTdpZy1qNDJaWm9SN0FzZDU1dw?oc=5","date":"2022-10-20","type":"deal","source":"Pharmaceutical Technology","summary":"Advaxis enters merger deal with biotech firm Ayala - Pharmaceutical Technology","headline":"Advaxis enters merger deal with biotech firm Ayala","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQOHdXM3JNVDVmUUU5NW96NGlSa2VrS01MNUpMRWZGWFEyT2hEelBWTFQ3b0ZrYUVlR2czYklDZmwzNXFXMldQODBGQTU2YlFvSVpLRS02THRVMjZ5OFhHNDdjN0x6ek56c3l1dHpIS2FWbThYUTNENXFqRzF6dzU4d2dOZ3E0bTdpRkVmTDNtbVlzRzk5dFFIWXpJSHEyV2YtVnFhT0xaZllzekJG?oc=5","date":"2022-09-14","type":"trial","source":"Labiotech.eu","summary":"Ayala Pharmaceuticals presents interim data on desmoid tumor trial - Labiotech.eu","headline":"Ayala Pharmaceuticals presents interim data on desmoid tumor trial","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}